0001493152-24-029174.txt : 20240726 0001493152-24-029174.hdr.sgml : 20240726 20240726093010 ACCESSION NUMBER: 0001493152-24-029174 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240725 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immix Biopharma, Inc. CENTRAL INDEX KEY: 0001873835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 454869378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41159 FILM NUMBER: 241143753 BUSINESS ADDRESS: STREET 1: 11400 WEST OLYMPIC BLVD. STREET 2: SUITE 200 CITY: LOS ANGELES STATE: CA ZIP: 90064 BUSINESS PHONE: (888) 958-1084 MAIL ADDRESS: STREET 1: 10573 W. PICO BLVD. STREET 2: #58 CITY: LOS ANGELES STATE: CA ZIP: 90064 8-K 1 form8-k.htm
false 0001873835 0001873835 2024-07-25 2024-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 25, 2024

 

IMMIX BIOPHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-41159   45-4869378

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

11400 West Olympic Blvd., Suite 200

Los Angeles, CA 90064

(Address of principal executive offices)

 

(310) 651-8041

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b)of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value of $0.0001 per share   IMMX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On July 25, 2024, Immix Biopharma, Inc. (the “Company”) filed a press release announcing that Nexcella, Inc., its wholly-owned subsidiary, has been awarded a $8 million grant from the California Institute for Regenerative Medicine. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01 in its entirety by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number		   Exhibit Description
99.1   Press Release, dated July 25, 2024
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Immix Biopharma, Inc.
   
Dated: July 26, 2024 /s/ Ilya Rachman
  Ilya Rachman
  Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

California Institute for Regenerative Medicine Awards Funding for

CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

 

  ● $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis

 

LOS ANGELES, July 25, 2024 (GLOBE NEWSWIRE) – Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma cell therapy division Nexcella an $8 million CLIN2 grant award to support clinical development of chimeric antigen receptor T-cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.

 

“AL amyloidosis is an unmet medical need, and current approved therapies for this rare disease are mostly not well tolerated and have not led to sustained remissions,” said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. “This one-time therapy would be an innovative treatment for patients with AL Amyloidosis, and the preliminary data are encouraging.”

 

“We are grateful for the recognition from CIRM of the importance of NXC-201 in relapsed/refractory AL Amyloidosis, for which there are no FDA approved drugs today,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “We are excited to join California’s thriving CIRM biotechnology innovation ecosystem as we proceed on-plan with NEXICART-2.”

 

The NEXICART-2 U.S. study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. The study builds on positive data from the initial ex-U.S. study, NEXICART-1, presented at the 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT 2024) which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients (12/13). The best responder experienced a 28.0 month duration of response (as reported May 10, 2024, with ongoing follow-up).

 

NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled “Systemic Light Chain Amyloidosis” published in June, 2024 New England Journal of Medicine .

 

About the California Institute for Regenerative Medicine (CIRM)

 

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies.

 

 

 

 

With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.

 

About NEXICART-2

 

NEXICART-2 (NCT06097832) is an open-label, single-arm, multi-site U.S. Phase 1b/2 dose expansion clinical trial of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 is expected to enroll 40 patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. The study is designed with a standard 6 patient safety-run in to evaluate two doses (three patients each at 150 million CAR+T cells and 450 million CAR+T cells), with the potential for further escalation to 800 million CAR+T cells (all 3 dose levels were evaluated in the NEXICART-1 study and have produced complete responses in relapsed/refractory AL Amyloidosis patients). The study aims to evaluate the safety and efficacy of NXC-201 in this patient population. Primary endpoints are complete response rate and overall response rate, according to consensus recommendations (Palladini et al. 2012).

 

About NEXICART-1

 

NEXICART-1 (NCT04720313) is an open-label, ex-U.S. Phase 1b/2a clinical trial of NXC-201 (formerly HBI0101) in patients with relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis (including AL Amyloidosis patients with impaired cardiac function and including AL Amyloidosis patients exposed to prior BCMA-targeted therapy). The primary objective of the study is to characterize the safety and efficacy, as well as confirm the recommended Phase 2 dose (RP2D) of NXC-201 (which has already been confirmed). NEXICART-1 clinical results, most recently from ASGCT 2024, are available at https://immixbio.com/pipeline/#publications.

 

About NXC-201

 

NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2a ex-U.S. study NEXICART-1 has demonstrated short duration of cytokine release syndrome (CRS) and no grade 3 or delayed neurotoxicity in high-volume disease, as well as short duration CRS and no neurotoxicity of any kind in AL Amyloidosis.

 

NXC-201 is being studied in a comprehensive clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, with the potential to expand into autoimmune indications. The NXC-201 NEXICART-2 U.S. clinical trial builds on a robust clinical dataset. NXC-201 has been awarded Orphan Drug Designation (ODD) in the US by the FDA and in the EU by the EMA in AL Amyloidosis.

 

About AL Amyloidosis

 

AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread damage to multiple organs, including heart failure, and leads to high mortality rates.

 

 

 

 

The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024.

 

The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.

 

About Immix Biopharma, Inc.

 

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2a trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated short duration of cytokine release syndrome (CRS) and no grade 3 or delayed neurotoxicity in high-volume disease, as well as short duration CRS and no neurotoxicity of any kind in AL Amyloidosis, supporting expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) in the US by the FDA and in the EU by the EMA in AL Amyloidosis. Learn more at www.immixbio.com and www.BeProactiveInAL.com.

 

About Nexcella, Inc.

 

As of May 2024, Nexcella, Inc. is a wholly-owned subsidiary of, and the cell therapy division of, Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX).

 

Forward Looking Statements

 

This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the receipt of, timing of receipt, finalization of the terms of, and allocation of funds in connection with, the grant discussed above and potential benefits of our product candidate CAR-T NXC-201. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1b/2a clinical trials for CAR-T NXC-201 will not be favorably consistent with the initial data initial data readouts, (ii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iii) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iv) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2024 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contacts

 

Mike Moyer

LifeSci Advisors

mmoyer@lifesciadvisors.com

 

Company Contact

 

irteam@immixbio.com

 

 

 

 EX-101.SCH 3 immx-20240725.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 immx-20240725_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 immx-20240725_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 25, 2024
Entity File Number 001-41159
Entity Registrant Name IMMIX BIOPHARMA, INC.
Entity Central Index Key 0001873835
Entity Tax Identification Number 45-4869378
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11400 West Olympic Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90064
City Area Code (310)
Local Phone Number 651-8041
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value of $0.0001 per share
Trading Symbol IMMX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immixbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm immx-20240725.xsd immx-20240725_lab.xml immx-20240725_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "IMMX", "nsuri": "http://immixbio.com/20240725", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "immx-20240725.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "immx-20240725_lab.xml" ] }, "presentationLink": { "local": [ "immx-20240725_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://immixbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://immixbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-029174-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-029174-xbrl.zip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end XML 16 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001873835 2024-07-25 2024-07-25 iso4217:USD shares iso4217:USD shares false 0001873835 8-K 2024-07-25 IMMIX BIOPHARMA, INC. DE 001-41159 45-4869378 11400 West Olympic Blvd. Suite 200 Los Angeles CA 90064 (310) 651-8041 false false false false Common Stock, par value of $0.0001 per share IMMX NASDAQ true false